Somatostatin receptors imaging in gastroenteropancreatic neuroendocrine tumors;Imagerie des recepteurs de la somatostatine dans les tumeurs neuroendocrines gastroenteropancreatiques

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 10, 1998, Pages 809-819

  Mure, Agnès ^a   Lebtahi, Rachida ^b   De Labriolle Vaylet, Claire ^a   Askienazy, Serge ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Neuroendocrine gastroenteropancreatic tumors; Octreotide; Scintigraphy; Somatostatin; Somatostatin receptors

Indexed keywords

(3 IODOBENZYL)GUANIDINE; OCTREOTIDE; SOMATOSTATIN RECEPTOR; RADIOPHARMACEUTICAL AGENT;

HUMAN; INTESTINE TUMOR; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; REVIEW; STOMACH TUMOR; TUMOR DIAGNOSIS; TUMOR SCINTISCANNING; AMINO ACID SEQUENCE; CHEMISTRY; GASTROINTESTINAL TUMOR; MOLECULAR GENETICS; PEROPERATIVE CARE; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AMINO ACID SEQUENCE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTRAOPERATIVE CARE; MOLECULAR SEQUENCE DATA; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN;

EID: 0031794892     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996;111:845-54.
2. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long lerm study. Gastroenterology 1995;108:1637-49.
3. Mozzel E. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis and treatment. Curr Probl Surg 1990;27:309-86.
4. Reubi JC. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
5. Reuhi JC, Laissue J, Krenning E, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J steroid Biochem Mol Biol 1992;43:27-35.
6. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-77.
7. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP, Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-9.
8. 111In-DTPA-D-PhcI)-octreotide; a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-91.
9. 111In-DTPA-D-PheI)-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593-601.
10. 3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
11. Lebtahi R, Petegnief Y, Delahaye N, Cadiot G, Sarda L, Faraggi M, et al. Abdominal spect versus planar somatostatin receptor scintigraphy in the detection of gastro-entero-pancreatic (GEP) tumors. Eur J Nucl Med 1995;22:P900.
12. Dörr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993;20:431-3.
13. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Œi HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-I-octreotide in man: metabolism, dosimetry and comparison with Iodine-123-tyr-3-octreotidc. J Nucl Med 1992;33:652-8.
14. Kwekkeboom DJ, Krenning EP, Bakker WH, Œi HY, Kooij PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993;20:283-92.
15. De Kerviler E, Cadiot G, Lebtahi R, Faraggi M, Le Guludec D, Mignon M, et al. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med 1994;21:1191-7.
16. King CMP, Reznek RH, Bomanji J, Britton KE, Grossman AB, Besser GB. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-Ray computer tomography: a comparative study. Clin Radiol 1993;48:386-91.
17. 111In-DTPA-D-PheI]-octreotide. Acta Oncol 1993;32:783-6.
18. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors. Gastroenterol 1994;32:323-7.
19. Scherübl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993;105:1705-9.
20. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with Indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36:542-9.
21. 111In-pentelreotidc for endocrine gastroenteropancreatic tumors. Horm metab res 1992;27:28-35.
22. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. Nucl Med Annu 1995:1-50.
23. Dörr U, Sautter-Bihl ML, Mcinckc J, Iser G, Ruth U, Buhr HJ, et al. Detection of neuroendocrine tumors of the gastro-intestinal tract by means of somatostatin receptor scintigraphy. J Nucl Med 1993;34:97P.
24. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996;125:26-34.
25. Schirmer WJ, Melvin WS, Rush RM, O'Dorisio TM, Pozderac RV, Olsen JO, et al. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery 1995;118:1105-14.
26. Bottger TC, Weber W, Beyer J, Junginger T. World Value of tumor localization in patients with insulinoma. World J Surg 1990;14:107-14.
27. Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet cell tumors. Surgery 1986;99:671-8.
28. Caliber AK, Reading CC, Charboneau JW, Sheedy PF, James EM, Gorman B, et al. Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. Radiology 1988;166:405-8.
29. Günther RW, Klose KJ, Rückert K, Kuhn FP, Beyer J, Klotter HJ, et al. Islet-cell tumors: detection of small lesions with computed tomography and ultrasound. Radiology 1983;148:485-8.
30. Hemmingsson A, Lindgren PG, Lörelius LE, Öberg K. Diagnosis of endocrine gastrointestinal tumours. Acta Radiol 1981;22:657-61.
31. Krudy AG, Doppman JL, Jensen RT, Norton JA, Collen MJ, Shawker TH, et al. Localization of islet cell tumors by dynamic CT. Comparison with plain CT, arteriography, sonography, and venous sampling. AJR 1984;143:585-9.
32. Norton JA, Doppman JL, Collen MJ. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986;204:468-79.
33. Päivansalo M, Mäkäräinen H, Sinuluoto T, Stahlberg M, Jalovaara P. Ultrasound compared with computed tomography and pancreatic arteriography in the detection of endocrine tumours of the pancreas. Eur J Radiol 1989;9:173-8.
34. Stark DD, Moss AA, Goldberg HJ, Deveney CW. CT of pancreaticislet cell tumors. Radiology 1984;150:491-4.
35. Wank SA, Doppman JL, Miller DL, Collen MJ, Maton PN, Vinayek R, et al. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987;92:905-12.
36. Cadiot G, Bonnaud G, Lebtahi R, Sarda L, Ruszniewski P, Lc Guludec D, et al. The usefulness of somatostatin-receptor scintigraphy in the management of patients with the Zollinger-Ellison syndrome. Gut 1997;41:107-14.
37. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-47.
38. Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996;39:562-8.
39. Nocaudie-Calzada M, Huglo D, Carnaille B, Proye C, Marchandise X. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 1996;23:1448-54.
40. Tenenbaum F, Lumbroso J. La scintigraphie des récepteurs de la somatostatine en pathologie digestive. Med Nucl Imagerie Fonct Metab 1996;20:295-321.
41. Lebtahi R, Sarda L, Cadiot G, Daou D, Faraggi M, Mignon M, et al. Detection of bone metastases in neuroendocrine gastroenteropancreatic (GEP) tumors: comparison of bone and somatostatin receptor scintigraphy. J Nucl Med 1995;36:127P.
42. Gibril F, Termanini B, Stewart CA, Sutliff VE, Jensen RT. Prospective study of the occurrence of metastases to bone in patients with Zollinger Ellison syndrome (abstract). Gastroenterology 1996;110:A1073.
43. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JGH, Lamberts SWJ. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988;95:760-3.
44. Van Eijck CHJ, Lamberts SWJ, Lemaire LCJM, Jeekel H, Bosman FT, Reubi JC, et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996;224:119-24.
45. Termanini B, Gibril F, Doppman JL, Reynolds JC, Stewart CA, Sutliff VE, et al. Distinguishing small hepatic hemangiomas from vascular liver metastases in gastrinoma: use of a somatostatin-receptor scintigraphy agent. Radiology 1997;202:151-8.
46. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patient with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-8.
47. Lebtahi R, Cadiot G, Marmuse JP, Vissuzaine C, Petegnief Y, Courillon-Mallet A, et al. False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med 1997;38:1979-81.
48. Baudin E, Giammarile F, Lumbroso J, Schlumberger M, Ducreux M, Rougier P, et al. Positivité de la scintigraphie à l'octréotide chez les patients porteurs de tumeurs neuro-endocrines: importance du site anatomique et de la différenciation tumorale. Med Nucl 1994;18:239P.
49. Zimmer T, Ziegler K, Bäder M, Fett U, Hamm B, Riecken EO, et al. Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Gut 1994;35:471-5.
50. Schillaci O, Annibale B, Scopinaro F, Delle Fave G, Centi Colella A. Somatostatin receptor scintigraphy of malignant somatostatinoma wilh indium-111-pentetreotide. J Nucl Med 1997;38:886-7.
51. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561-81.
52. Gibril F, Fraker DL, Alexander HR, Termanini B, Stewart CA, Sutliff VE, et al. Does the use of preoperative somatostatin receptor scintigraphy (SRS) have an impact in improving postoperative curerate in patients undergoing surgery with Zollinger Ellison syndrome (ZES): a prospective study. Gastroenterology 1996;110:A391.
53. Nocaudie-Calzada M, Huglo D, Deveaux M, Carnaille B, Proye C, Marchandise X. Iodine-123-tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide. J Nucl Med 1994;35:57-62.
54. 1)octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577-81.
55. Trautmann ME, Neuhaus Ch, Lenze H, Benning R, Benning M, Dennler HJ, et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Horm Metab Res 1992;27:24-7.
56. 111In-DTPA-D-Phel]octreotide. Eur J Nucl Med 1994;21:328-35.
57. Béhé M, Mäcke HR. New somatostatin analogues labelled with technetium 99-m. Eur J Nucl Med 1995;22:P791.
58. TM for imaging somatostatin receptors in vivo. J Nucl Med 1995;36:P91.
59. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyal S, Yang Q, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-21.
60. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging, J Nucl Med 1995;36:1846-53.
61. 125I-TYR(3)-etreotide and a hand-held gamma-detecting probe. Surgery 1993;114:745-52.
62. 125-labeled lanreotide and intraoperative gamma detection. Surgery 1994;116:1139-47.
63. Baum RP, Adams S, Wenisch HJC, Lorenz M, Staib-Sebler E, Niesen A, et al. Localization of endocrine tumors can be improved by peri-operative radiodetection (POB) using a hand-held gamma probe. J Nucl Med 1995;36:P202.
64. Meunier B, Le Cloirec J, Dazord L, Leveque J, Lesimple T, Tas P, et al. Per operative localization of a carcinoid tumour of the breast using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1995;22:281-3.
65. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1994;2:363-4.
66. Öhrvall U, Lundqvist H, Westlin JE, Nilsson S, Juhlin C, Rastad J, et al. Development of an intraoperative gamma-detector probe for intraoperative use - a valuable complement to octreotide scintigraphy. Eur J Nucl Med 1995;22:P815.
67. Petegnief Y, Lebtahi R, Cadiot G, Marmuse JP, Vissuzaine C, Sarda L, et al. A prospective study of the value of intraoperative detection of gastro-entero-pancreatic (GEP) tumours with In 111 pentetreotide. Eur J Nucl Med 1996;23:1063.
68. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med 1995;22:608-16.
69. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995;25:272-8.
70. Forssell-Aronsson E, Fjälling M, Nilsson O, Tisell LE, Wängberg B, Ahlman H, et al. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med 1995;36:7-12.
71. Krenning EP, Kooij PPM, Pauwels S, Breeman WAP, Postema PTE, De Herder WW, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57(suppl 1):57-61.